Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management

Authors


  • Potential conflict of interest: Dr. Lok receives research support and serves on advisory board of GlaxoSmithKline, Gilead, Bristol Myers Squibb, Idenix, Roche Molecular Diagnostics and Innogenetics. Dr. Zoulim serves on advisory board of Gilead, Idenix, Bristol Myers Squibb, Innogenetics and receives research support from bioMerieux. Dr. Locarnini receives research support and serves on advisory board of Gilead Sciences, Bristol-Myers Squibb, Pharmasset, LG Sciences, Innogenetics and Evivar Pty Ltd. Dr. Bartholomeusz is a Consultant to Evivar Medical Pty Ltd. Dr. Pawlotsky receives research support and/or serves on advisory board of GlaxoSmithKline, Gilead, Bristol-Myers Squibb, Idenix and Novartis. Dr. Liaw receives research support and serves on advisory board and speaker bureau of Roche, Bristol-Myers Squibb, GlaxoSmithKline, and Idenix.

Abstract

Substantial advances have been made in the treatment of chronic hepatitis B in the past decade. Approved treatments for chronic hepatitis B include 2 formulations of interferon and 4 nucleos(t)ide analogues (NAs). Sustained viral suppression is rarely achieved after withdrawal of a 48-week course of NA therapy, necessitating long, and in many cases, indefinite treatment with increasing risk of development of drug resistance. Antiviral resistance and poor adherence are the most important factors in treatment failure of hepatitis B. Thus, there is a need to standardize nomenclature relating to hepatitis B antiviral resistance, and to define genotypic, phenotypic, and clinical resistance to NA therapy. (HEPATOLOGY 2007;46:254–265.)

Ancillary